Tennessee Senate Bill SB1256

Tennessee 2025-2026 Regular Session

• Introduced: 2/6/25

Caption

AN ACT to amend Tennessee Code Annotated, Title 8; Title 33; Title 53; Title 56; Title 63; Title 68 and Title 71, relative to prescription drugs.

Summary

SB1256 requires the Tennessee Department of Finance and Administration, working with the Department of Health and TennCare, to seek federal approval by January 1, 2026, to import safe and effective prescription drugs from Canada under federal law. The request to the U.S. Secretary of Health and Human Services must show that imported drugs will meet safety, effectiveness, and supply-chain security standards, identify drugs with the greatest potential for savings, estimate annual savings and costs, and list compliant Canadian suppliers. If federal approval is granted, the department must notify state legislative and executive leaders and, within six months, submit a proposal for implementing a Canadian drug importation program focused on the drugs most likely to reduce state costs. The bill also authorizes the relevant agencies to adopt rules to carry out the program under Tennessee’s administrative rulemaking procedures.

Impact

The bill would add a new section to Tennessee Code Annotated Title 53 and direct state agencies to pursue a federally authorized prescription drug importation pathway from Canada. It does not itself create an operating importation program immediately; instead, it establishes a planning, application, and implementation framework that could affect state procurement, TennCare spending, and pharmaceutical distribution rules if federal approval is obtained. It also authorizes rulemaking by the Department of Finance and Administration, the Department of Health, and TennCare.

Sentiment

Based on the bill text and the absence of recorded committee discussion or votes in the provided materials, the measure appears to be framed as a cost-savings and access initiative rather than a controversial policy change on its face. The bill’s structure suggests support for exploring lower-cost prescription drug options while emphasizing compliance with federal and safety requirements. No recorded vote history or transcript is available here to indicate broader legislative sentiment.

Contention

The main potential points of contention are likely to be the safety, legality, and practical feasibility of importing prescription drugs from Canada, as well as whether projected savings would outweigh implementation and compliance costs. Stakeholders concerned about pharmaceutical supply-chain integrity, federal preemption, or impacts on domestic drug markets may question the proposal, while supporters would likely emphasize lower costs for the state and TennCare. Because no committee transcript or vote record is provided, no specific member or group opposition is documented in the supplied materials.